S-1 in the treatment of advanced and recurrent gastric cancer: Current state and future prospects

Ikuo Takahashi, Yoshihiro Kakeji, Yasunori Emi, Masato Sakurai, Yusuke Yonemura, Yasue Kimura, Yoshihiko Maehara

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background. S-1 (TS-1®) is a novel oral anticancer drug. Because of the excellent results of phase II studies, we continued to prescribe S-1 for advanced or recurrent gastric cancer after we participated in the phase I and II studies. Methods. Twenty-nine patients with advanced or recurrent gastric cancer were treated with S-1. Clinicopathological features, survival, and adverse reactions were analyzed. Results. One course of treatment consisted of 40, 50, or 60 mg/body twice a day for 28 days followed by withdrawal for 2 weeks. The mean number of treatments was 3.6 courses (range, 1-12 courses). The response rate was 37.9% (11 partial responses [PRs] in 29 patients). Although the response rate of patients who did not receive prior chemotherapy was 47.6% (10 PRs in 21 patients), that of patients with prior chemotherapy was 12.5% (1 PR in 8 patients). The median survival time was 14.1 months, and that of patients who responded to treatment was 22.1 months, which was significantly longer than that of nonresponder patients. One-year and 2-year survivals in the 29 patients were 50.2% and 24.3%, respectively. Adverse reactions were noted in 17 of 29 patients, and the most frequent one was leukocytopenia. Only 2 patients experienced grade 3 leukocytopenia and neutrocytopenia. Conclusion. Because of the high response rate and low incidence of severe adverse reactions, S-1 is a first-line chemotherapy that can be used for outpatients, especially for patients without prior chemotherapy. As the response rate for patients with prior chemotherapy was low, combined therapy with S-1 is worth evaluating for these patients.

Original languageEnglish
Pages (from-to)28-33
Number of pages6
JournalGastric Cancer
Volume6
Issue numberSUPPL. 1
DOIs
Publication statusPublished - Jun 2 2003

Fingerprint

Stomach Neoplasms
Therapeutics
Drug Therapy
Leukopenia
Survival
Outpatients

All Science Journal Classification (ASJC) codes

  • Oncology
  • Gastroenterology
  • Cancer Research

Cite this

S-1 in the treatment of advanced and recurrent gastric cancer : Current state and future prospects. / Takahashi, Ikuo; Kakeji, Yoshihiro; Emi, Yasunori; Sakurai, Masato; Yonemura, Yusuke; Kimura, Yasue; Maehara, Yoshihiko.

In: Gastric Cancer, Vol. 6, No. SUPPL. 1, 02.06.2003, p. 28-33.

Research output: Contribution to journalArticle

Takahashi, I, Kakeji, Y, Emi, Y, Sakurai, M, Yonemura, Y, Kimura, Y & Maehara, Y 2003, 'S-1 in the treatment of advanced and recurrent gastric cancer: Current state and future prospects', Gastric Cancer, vol. 6, no. SUPPL. 1, pp. 28-33. https://doi.org/10.1007/s10120-003-0228-5
Takahashi, Ikuo ; Kakeji, Yoshihiro ; Emi, Yasunori ; Sakurai, Masato ; Yonemura, Yusuke ; Kimura, Yasue ; Maehara, Yoshihiko. / S-1 in the treatment of advanced and recurrent gastric cancer : Current state and future prospects. In: Gastric Cancer. 2003 ; Vol. 6, No. SUPPL. 1. pp. 28-33.
@article{86d540908d7040c7983b5884337eae36,
title = "S-1 in the treatment of advanced and recurrent gastric cancer: Current state and future prospects",
abstract = "Background. S-1 (TS-1{\circledR}) is a novel oral anticancer drug. Because of the excellent results of phase II studies, we continued to prescribe S-1 for advanced or recurrent gastric cancer after we participated in the phase I and II studies. Methods. Twenty-nine patients with advanced or recurrent gastric cancer were treated with S-1. Clinicopathological features, survival, and adverse reactions were analyzed. Results. One course of treatment consisted of 40, 50, or 60 mg/body twice a day for 28 days followed by withdrawal for 2 weeks. The mean number of treatments was 3.6 courses (range, 1-12 courses). The response rate was 37.9{\%} (11 partial responses [PRs] in 29 patients). Although the response rate of patients who did not receive prior chemotherapy was 47.6{\%} (10 PRs in 21 patients), that of patients with prior chemotherapy was 12.5{\%} (1 PR in 8 patients). The median survival time was 14.1 months, and that of patients who responded to treatment was 22.1 months, which was significantly longer than that of nonresponder patients. One-year and 2-year survivals in the 29 patients were 50.2{\%} and 24.3{\%}, respectively. Adverse reactions were noted in 17 of 29 patients, and the most frequent one was leukocytopenia. Only 2 patients experienced grade 3 leukocytopenia and neutrocytopenia. Conclusion. Because of the high response rate and low incidence of severe adverse reactions, S-1 is a first-line chemotherapy that can be used for outpatients, especially for patients without prior chemotherapy. As the response rate for patients with prior chemotherapy was low, combined therapy with S-1 is worth evaluating for these patients.",
author = "Ikuo Takahashi and Yoshihiro Kakeji and Yasunori Emi and Masato Sakurai and Yusuke Yonemura and Yasue Kimura and Yoshihiko Maehara",
year = "2003",
month = "6",
day = "2",
doi = "10.1007/s10120-003-0228-5",
language = "English",
volume = "6",
pages = "28--33",
journal = "Gastric Cancer",
issn = "1436-3291",
publisher = "Springer Japan",
number = "SUPPL. 1",

}

TY - JOUR

T1 - S-1 in the treatment of advanced and recurrent gastric cancer

T2 - Current state and future prospects

AU - Takahashi, Ikuo

AU - Kakeji, Yoshihiro

AU - Emi, Yasunori

AU - Sakurai, Masato

AU - Yonemura, Yusuke

AU - Kimura, Yasue

AU - Maehara, Yoshihiko

PY - 2003/6/2

Y1 - 2003/6/2

N2 - Background. S-1 (TS-1®) is a novel oral anticancer drug. Because of the excellent results of phase II studies, we continued to prescribe S-1 for advanced or recurrent gastric cancer after we participated in the phase I and II studies. Methods. Twenty-nine patients with advanced or recurrent gastric cancer were treated with S-1. Clinicopathological features, survival, and adverse reactions were analyzed. Results. One course of treatment consisted of 40, 50, or 60 mg/body twice a day for 28 days followed by withdrawal for 2 weeks. The mean number of treatments was 3.6 courses (range, 1-12 courses). The response rate was 37.9% (11 partial responses [PRs] in 29 patients). Although the response rate of patients who did not receive prior chemotherapy was 47.6% (10 PRs in 21 patients), that of patients with prior chemotherapy was 12.5% (1 PR in 8 patients). The median survival time was 14.1 months, and that of patients who responded to treatment was 22.1 months, which was significantly longer than that of nonresponder patients. One-year and 2-year survivals in the 29 patients were 50.2% and 24.3%, respectively. Adverse reactions were noted in 17 of 29 patients, and the most frequent one was leukocytopenia. Only 2 patients experienced grade 3 leukocytopenia and neutrocytopenia. Conclusion. Because of the high response rate and low incidence of severe adverse reactions, S-1 is a first-line chemotherapy that can be used for outpatients, especially for patients without prior chemotherapy. As the response rate for patients with prior chemotherapy was low, combined therapy with S-1 is worth evaluating for these patients.

AB - Background. S-1 (TS-1®) is a novel oral anticancer drug. Because of the excellent results of phase II studies, we continued to prescribe S-1 for advanced or recurrent gastric cancer after we participated in the phase I and II studies. Methods. Twenty-nine patients with advanced or recurrent gastric cancer were treated with S-1. Clinicopathological features, survival, and adverse reactions were analyzed. Results. One course of treatment consisted of 40, 50, or 60 mg/body twice a day for 28 days followed by withdrawal for 2 weeks. The mean number of treatments was 3.6 courses (range, 1-12 courses). The response rate was 37.9% (11 partial responses [PRs] in 29 patients). Although the response rate of patients who did not receive prior chemotherapy was 47.6% (10 PRs in 21 patients), that of patients with prior chemotherapy was 12.5% (1 PR in 8 patients). The median survival time was 14.1 months, and that of patients who responded to treatment was 22.1 months, which was significantly longer than that of nonresponder patients. One-year and 2-year survivals in the 29 patients were 50.2% and 24.3%, respectively. Adverse reactions were noted in 17 of 29 patients, and the most frequent one was leukocytopenia. Only 2 patients experienced grade 3 leukocytopenia and neutrocytopenia. Conclusion. Because of the high response rate and low incidence of severe adverse reactions, S-1 is a first-line chemotherapy that can be used for outpatients, especially for patients without prior chemotherapy. As the response rate for patients with prior chemotherapy was low, combined therapy with S-1 is worth evaluating for these patients.

UR - http://www.scopus.com/inward/record.url?scp=0037570591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037570591&partnerID=8YFLogxK

U2 - 10.1007/s10120-003-0228-5

DO - 10.1007/s10120-003-0228-5

M3 - Article

C2 - 12775017

AN - SCOPUS:0037570591

VL - 6

SP - 28

EP - 33

JO - Gastric Cancer

JF - Gastric Cancer

SN - 1436-3291

IS - SUPPL. 1

ER -